SCHEMBL5653250

SCHEMBL5653250

CCOc1cc(C(=O)NCCCN2CCOCC2)ccc1-c1nc2cc3ccccc3cc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.55
USP2 O75604 1/20 0.55
HTT P42858 1/20 0.55
HSD17B10 Q99714 1/20 0.55
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 1/20 0.53
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GAA P10253 1/20 0.49
CDK4 P11802 1/20 0.48
CCNA2 P20248 1/20 0.48
CCND1 P24385 1/20 0.48
CDK2 P24941 1/20 0.48
CCND3 P30281 1/20 0.48
UBE2N P61088 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651317 0.92 CYP2D6 (0.61) TSHRHSD17B10CYP2D6CYP2C9CYP1A2
SCHEMBL5651323 0.91 TSHR (0.53) TSHRUSP2HTTHSD17B10CYP2D6
SCHEMBL5650235 0.89 CYP2C9 (0.56) TSHRUSP2HTTHSD17B10CYP2D6
SCHEMBL5650259 0.89 MEN1 (0.57) TSHRUSP2HTTHSD17B10CYP2D6
SCHEMBL5650720 0.89 TSHR (0.53) TSHRUSP2HTTHSD17B10CYP2D6
SCHEMBL5650726 0.89 TSHR (0.53) TSHRUSP2HTTHSD17B10CYP2D6
SCHEMBL5653961 0.88 TSHR (0.51) TSHRUSP2HTTHSD17B10CYP2D6
SCHEMBL5653958 0.88 TSHR (0.51) TSHRUSP2HTTHSD17B10CYP2D6
SCHEMBL5654035 0.88 CYP2D6 (0.53) TSHRUSP2HTTHSD17B10CYP2D6
SCHEMBL5649128 0.86 TSHR (0.51) TSHRUSP2HTTHSD17B10CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 TSHR 161/4885USP2 2183/4885HTT 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.